RxDoctor Payments DataLook up a doctor →

Mark Davis, PA

Medical · Fort Worth, TXNPI 1679580435

Payments from drug & device makers

$1,038,650in general payments, 2019–2025

Across 2,269 payments — averaging $457.76 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$280K
  • GSK$201K
  • Incyte Corporation$104K
  • Sobi, Inc$83K
  • Takeda Pharmaceuticals U.S.A., Inc.$70K
  • CTI Biopharma Corp.$58K
  • plus $243K from 54 others

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Johnson & Johnson(3 entities)529$279,753
GSK237$200,967
Incyte Corporation303$104,327
Sobi, Inc122$83,012
Takeda Pharmaceuticals U.S.A., Inc.109$70,034
CTI Biopharma Corp.67$57,769
E.r. Squibb & Sons, L.L.C.107$42,129
Jazz Pharmaceuticals Inc.97$41,325
Regeneron Healthcare Solutions, Inc.83$29,579
AstraZeneca(2 entities)76$27,995
Rigel Pharmaceuticals, Inc.42$22,911
Geron Corporation25$19,288
Bristol Myers Squibb37$18,091
Mirati Therapeutics, Inc.30$8,685
Karyopharm Therapeutics Inc.24$5,675
Epizyme, Inc.17$3,749
Genmab U.S., Inc.14$3,595
Merck27$3,300
Ipsen Biopharmaceuticals, Inc15$2,979
Amgen15$2,444
Beigene USA, Inc.5$1,148
Pharmaessentia USA Corporation7$1,097
Adaptive Biotechnologies Corporation18$768
Secura Bio, Inc.4$741
Janssen Scientific Affairs, LLC7$699
Eisai Inc.13$618
Gilead(2 entities)22$572
Lilly USA, LLC27$562
Pfizer25$558
Seagen Inc.17$481
Novartis20$455
AbbVie12$410
Astellas Pharma US Inc12$381
TG Therapeutics, Inc.3$286
Daiichi Sankyo Inc.11$264
Pharmacosmos Therapeutics Inc.8$182
Sanofi7$174
Array Biopharma Inc8$163
Tempus AI, Inc5$152
Genentech USA, Inc.7$136
Stemline Therapeutics Inc.6$131
Morphosys, US Inc.6$126
Deciphera Pharmaceuticals Inc.4$122
Boehringer Ingelheim5$102
Bayer5$97
EMD Serono, Inc.3$89
Servier Pharmaceuticals LLC4$86
Kyowa Kirin, Inc.3$71
Pharmacyclics LLC, An Abbvie Company2$48
Beone Medicines USA, Inc.2$45
Blueprint Medicines Corporation2$31
Puma Biotechnology, Inc.1$26
Syndax Pharmaceuticals, Inc.1$25
Exelixis Inc.1$23
Shield Therapeutics Inc1$22
ADC Therapeutics America, Inc.1$18
Taiho Oncology, Inc.1$18
Caris MPI, Inc.1$18
Tolmar Pharmaceuticals, Inc.1$17
Acceleron Pharma, Inc.1$17

How this compares

$1,038,650 in reported general payments places this provider in the 95th percentile of 1,490 medical providers in Texas.

See all medical providers in Texas →

Medicare billing

Part B allowed, 2024
$77,027
Medicare patients
278
Services billed
2,613

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other medical in Fort Worth

See the full list for Texas →

Where these figures come from

Is this you, or does something look wrong? →